Review of GLP-1 drug safety and efficacy in special populations provides guidance for prescribing in complex patients with multiple comorbidities.
Key findingReview of GLP-1 drug safety and efficacy in special populations provides guidance for prescribing in
What the researchers found
Review of GLP-1 drug safety and efficacy in special populations provides guidance for prescribing in complex patients with multiple comorbidities.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
Meta-analysis of RCTs from four databases. Approximately one billion people affected by OSA worldwide.
How the study worked
In publication.
Who was studied
Adults with obstructive sleep apnea in randomized controlled trials
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.
European clinical respiratory journal, 12(1), 2484048
Citation
Altobaishat, Obieda; Farid Gadelmawla, Ahmed; Balbaa, Elsayed; Turkmani, Mustafa; Abouzid, Mohamed. (2025). Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials.. European clinical respiratory journal, 12(1), 2484048. https://doi.org/10.1080/20018525.2025.2484048